ATE421092T1 - Verwendung von gfap zum nachweis von intrazerebraler blutung - Google Patents
Verwendung von gfap zum nachweis von intrazerebraler blutungInfo
- Publication number
- ATE421092T1 ATE421092T1 AT04765563T AT04765563T ATE421092T1 AT E421092 T1 ATE421092 T1 AT E421092T1 AT 04765563 T AT04765563 T AT 04765563T AT 04765563 T AT04765563 T AT 04765563T AT E421092 T1 ATE421092 T1 AT E421092T1
- Authority
- AT
- Austria
- Prior art keywords
- gfap
- intracerebral hemorrhage
- detecting
- early
- marker
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Prostheses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03021571A EP1519194A1 (de) | 2003-09-24 | 2003-09-24 | Die Verwendung von GFAP zur Identifizierung einer Intrazerebralblutung |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE421092T1 true ATE421092T1 (de) | 2009-01-15 |
Family
ID=34178487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04765563T ATE421092T1 (de) | 2003-09-24 | 2004-09-24 | Verwendung von gfap zum nachweis von intrazerebraler blutung |
Country Status (6)
Country | Link |
---|---|
US (3) | US20060240480A1 (de) |
EP (2) | EP1519194A1 (de) |
AT (1) | ATE421092T1 (de) |
DE (1) | DE602004019120D1 (de) |
ES (1) | ES2319299T3 (de) |
WO (1) | WO2005029087A1 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1519194A1 (de) | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Die Verwendung von GFAP zur Identifizierung einer Intrazerebralblutung |
US8492107B2 (en) | 2004-04-15 | 2013-07-23 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
EP2143735A1 (de) * | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable Domänen von Schwerketten-Antikörpern, die sich gegen GFAPs richten |
EP4235181A3 (de) * | 2008-08-11 | 2024-02-28 | Banyan Biomarkers Inc | Biomarkerdetektionsverfahren und test für neurologischen zustand |
EP3355059A3 (de) * | 2009-06-19 | 2018-09-26 | Banyan Biomarkers, Inc. | Biomarker-assay eines neurologischen zustands |
US20170315136A9 (en) * | 2009-06-19 | 2017-11-02 | Banyan Biomarkers, Inc. | Biomarker assay of neurological condition |
JP5909447B2 (ja) | 2009-09-14 | 2016-04-26 | バンヤン・バイオマーカーズ・インコーポレーテッド | ニューロン損傷診断のためのマイクロrna、自己抗体およびタンパク質マーカー |
RU2571489C2 (ru) | 2009-10-26 | 2015-12-20 | Нестек С.А. | Способы выявления препаратов и аутоантител против tnf |
WO2011160096A2 (en) * | 2010-06-17 | 2011-12-22 | Banyan Biomarkers, Inc. | Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition |
WO2012051519A2 (en) | 2010-10-14 | 2012-04-19 | The Johns Hopkins University | Biomarkers of brain injury |
BR112013009376A2 (pt) | 2010-10-18 | 2016-07-26 | Nestec Sa | métodos para determinar isótipos de anticorpos antifármacos |
US20130266963A1 (en) * | 2011-07-06 | 2013-10-10 | Nestec S.A. | Assay for detecting neutralizing autoantibodies to biologic therapy |
MX343324B (es) | 2011-07-06 | 2016-11-01 | Nestec Sa | Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha. |
CN102353787B (zh) * | 2011-09-27 | 2013-03-06 | 山东莱博生物科技有限公司 | 一种半定量检测人血清中gfap浓度的胶体金试纸条的制备方法 |
WO2013138509A1 (en) | 2012-03-13 | 2013-09-19 | The Johns Hopkins University | Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration |
CN104142404B (zh) * | 2013-05-10 | 2016-10-05 | 深圳市安群生物工程有限公司 | 检测人gfap蛋白的荧光免疫层析试纸及其制备方法 |
GB201309928D0 (en) * | 2013-06-04 | 2013-07-17 | Randox Lab Ltd | Method |
US10534003B2 (en) | 2013-07-17 | 2020-01-14 | The Johns Hopkins University | Multi-protein biomarker assay for brain injury detection and outcome |
EP3029466A1 (de) * | 2014-12-03 | 2016-06-08 | Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca | Verfahren zur Unterscheidung eines ischämischen Schlaganfalls von einem hämorrhagischem Schlaganfall |
BR112017011545A2 (pt) | 2014-12-05 | 2018-03-13 | Nestec Sa | ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente |
BR112019006710A2 (pt) * | 2016-10-03 | 2019-06-25 | Abbott Lab | métodos aprimorados para avaliação do estado da uch-l1 em amostras de pacientes |
GB201619823D0 (en) * | 2016-11-23 | 2017-01-04 | Randox Laboratories Ltd And Teoranta Randox | GFAP accumulating stroke |
CN109633171A (zh) * | 2018-12-29 | 2019-04-16 | 上海八通生物科技股份有限公司 | 快速检测gfap的荧光免疫层析试纸条及其制备与应用 |
WO2021009074A1 (en) | 2019-07-12 | 2021-01-21 | Adx Neurosciences Nv | Novel markers as early predictors of alzheimer's pathology |
JP2023551542A (ja) | 2020-11-30 | 2023-12-08 | エニグマ バイオインテリジェンス,インコーポレイテッド | アルツハイマー病の非侵襲的評価 |
CN114624448B (zh) * | 2022-03-18 | 2022-09-20 | 北京美联泰科生物技术有限公司 | 一种用于检测胶质纤维酸性蛋白的试剂盒 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3445816C1 (de) | 1984-12-15 | 1986-06-12 | Behringwerke Ag, 3550 Marburg | Flaechenfoermiges diagnostisches Mittel |
US4743542A (en) * | 1985-04-11 | 1988-05-10 | Ortho Diagnostic | Method for forestalling the hook effect in a multi-ligand immunoassay system |
GB8621261D0 (en) * | 1986-09-03 | 1986-10-08 | Barnard G J R | Enhanced luminescent assay |
US5733721A (en) * | 1992-11-20 | 1998-03-31 | The Board Of Regents Of The University Of Oklahoma | Cell analysis method using quantitative fluorescence image analysis |
US5750345A (en) * | 1995-10-31 | 1998-05-12 | Evanston Hospital Corporation | Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders |
US6449562B1 (en) * | 1996-10-10 | 2002-09-10 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
CA2263063C (en) * | 1999-02-26 | 2004-08-10 | Skye Pharmatech Incorporated | Method for diagnosing and distinguishing stroke and diagnostic devices for use therein |
US6664442B2 (en) | 2000-03-30 | 2003-12-16 | Elan Pharmaceuticals, Inc. | Selecting compounds to reduce inflammation associated with Alzheimer's disease |
US20040203083A1 (en) | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
US20030199000A1 (en) | 2001-08-20 | 2003-10-23 | Valkirs Gunars E. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
WO2003016910A1 (en) * | 2001-08-20 | 2003-02-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
IL159015A0 (en) * | 2001-05-25 | 2004-05-12 | Genset Sa | Polypeptides, their preparation and use |
US7144708B2 (en) | 2001-06-25 | 2006-12-05 | The Cleveland Clinic Foundation | Markers of blood barrier disruption and methods of using same |
AU2002329570A1 (en) | 2001-10-12 | 2003-01-30 | Pfizer Products Inc. | Method of monitoring neuroprotective treatment |
US7371582B2 (en) * | 2002-01-23 | 2008-05-13 | Boditechmed Inc. | Lateral flow quantitative assay method and strip and laser-induced fluorescence detection device therefor |
EP1551450A4 (de) | 2002-06-12 | 2005-11-23 | Cleveland Clinic Foundation | Marker für die permeabilität der blutbarriere und verfahren zu ihrer verwendung |
AU2003302340B8 (en) * | 2002-12-24 | 2008-09-11 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
EP2357477B1 (de) | 2003-09-20 | 2017-11-08 | Electrophoretics Limited | Diagnosenverfahren für Erkrankungen im Zusammenhang mit Hirnschäden basierend auf NDKA |
EP1519194A1 (de) | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Die Verwendung von GFAP zur Identifizierung einer Intrazerebralblutung |
US20050112585A1 (en) * | 2003-11-21 | 2005-05-26 | Dominic Zichi | Method for adjusting the quantification range of individual analytes in a multiplexed assay |
US8492107B2 (en) | 2004-04-15 | 2013-07-23 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
EP2207033B1 (de) | 2004-04-15 | 2014-06-18 | University of Florida Research Foundation, Inc. | Neuralproteine als Biomarker für Verletzungen des Nervensystems und anderen neuralen Störungen |
US7396689B2 (en) * | 2005-02-04 | 2008-07-08 | Decision Biomarkers Incorporated | Method of adjusting the working range of a multi-analyte assay |
EP4235181A3 (de) | 2008-08-11 | 2024-02-28 | Banyan Biomarkers Inc | Biomarkerdetektionsverfahren und test für neurologischen zustand |
-
2003
- 2003-09-24 EP EP03021571A patent/EP1519194A1/de not_active Withdrawn
-
2004
- 2004-09-24 DE DE602004019120T patent/DE602004019120D1/de active Active
- 2004-09-24 WO PCT/EP2004/010711 patent/WO2005029087A1/en active Application Filing
- 2004-09-24 EP EP04765563A patent/EP1668370B1/de active Active
- 2004-09-24 AT AT04765563T patent/ATE421092T1/de active
- 2004-09-24 ES ES04765563T patent/ES2319299T3/es active Active
-
2006
- 2006-03-23 US US11/388,156 patent/US20060240480A1/en not_active Abandoned
-
2015
- 2015-05-13 US US14/711,228 patent/US10794918B2/en active Active
-
2020
- 2020-09-03 US US17/011,924 patent/US20210102958A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10794918B2 (en) | 2020-10-06 |
ES2319299T3 (es) | 2009-05-06 |
US20210102958A1 (en) | 2021-04-08 |
EP1668370A1 (de) | 2006-06-14 |
EP1519194A1 (de) | 2005-03-30 |
EP1668370B1 (de) | 2009-01-14 |
US20150247867A1 (en) | 2015-09-03 |
US20060240480A1 (en) | 2006-10-26 |
DE602004019120D1 (de) | 2009-03-05 |
WO2005029087A1 (en) | 2005-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE421092T1 (de) | Verwendung von gfap zum nachweis von intrazerebraler blutung | |
ATE425266T1 (de) | Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten | |
ATE428929T1 (de) | Reagens, ausstattung und verfahren zur probenanalyse | |
CY1111229T1 (el) | Μεθοδος προσδιορισμου ρευματοειδους αρθριτιδας με μετρηση αντι-ccp και ιντερλευκλινης 6 | |
ATE409314T1 (de) | Verfahren zur beurteilung rheumatoider arthritis durch messen von anti-ccp und serumamyloid a | |
ATE462803T1 (de) | Kit und verfahren zum nachweis von urothelkarzinom | |
FR2895087B1 (fr) | Methode de discrimination d'au moins deux populations cellulaires et application | |
ATE370414T1 (de) | Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs | |
WO2005124356A3 (en) | Use of protein cbp2 as a marker for colorectal cancer | |
FR2894675B1 (fr) | Distinction des meningites bacteriennes et virales | |
HK1136873A1 (en) | Use of nnmt as a marker for lung cancer | |
ATE347105T1 (de) | Verfahren, assay und kit zur quantifizierung von hiv-proteasehemmer | |
ATE382861T1 (de) | Universeller biosensor und verfahren zur verwendung | |
WO2006066917A3 (en) | Use of asc as a marker for colorectal cancer | |
EP1610127A4 (de) | N1,n12-diacetylspermin als tumormarker | |
HK1091540A1 (en) | Use of a virus expressing a binding moiety to measure analytes in a sample | |
ATE455297T1 (de) | Mikrosensor zur bestimmung von d-aminosäuren | |
BRPI0704641A2 (pt) | kit de teste rápido e método para detecção e localização de úlceras e outros sangramentos do trato digestivo em equinos utilizando anticorpos monoclonais e policlonais de hemoglobina e albumina equina | |
DE60225168D1 (de) | Verfahren zur auswahl bioaktiver wirkstoffe durch lumineszenzkopplung und lebendes zellensystem dafür | |
ATE414904T1 (de) | Verfahren zum testen des oxidiertes-ldl-beta-2- glycoprotein-i-komplexes in vivo | |
ATE455305T1 (de) | Verfahren zur bestimmung des verhältnisses von zwei verschiedenen peptiden oder polynukleinsäuren | |
ATE403141T1 (de) | Verfahren und vorrichtung zur messung rheologischer stoffeigenschaften einer visko- elastischen probe. | |
WO2010006616A3 (en) | Method and kit for examination of cells using n-(9-acridinyl)maleimide (nam) or using 7-diethylamino-3-((4'-(iodoacetyl)amino)phenyl)-4-methylcoumarin (cpi) | |
TH183243A (th) | ชุดตรวจสอบความเป็นพิษโดยรวมและรูปแบบความเป็นพิษของสารตัวอย่าง จากแบคทีเรียและรีคอมบิแนนต์แบคทีเรีย และกรรมวิธีตรวจสอบ | |
BRPI0512611A (pt) | métodos e composições para a detecção de moléculas biológicas empregando um complexo de duas partìculas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1668370 Country of ref document: EP |